Market cap
$1,343 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-103 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-10.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7.1
-
Face value
--
-
Shares outstanding
24,419,300
9 Years Aggregate
CFO
$-358.58 Mln
EBITDA
$-428.44 Mln
Net Profit
$-491.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sierra Oncology (SRRA)
| 152.9 | 0.4 | 71.6 | 182.4 | 34.9 | 3.3 | -- |
|
BSE Sensex*
| -9.1 | 2.1 | 5.9 | -6.0 | 6.9 | 8.0 | 11.0 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|
|
Sierra Oncology (SRRA)
| 35.6 | 17.0 | -74.1 | -64.4 | 150.3 | -90.1 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sierra Oncology (SRRA)
|
55.0 | 1,342.8 | 0.0 | -102.7 | -- | -57.6 | -- | 5.1 |
| 848.9 | 54,853.1 | 6,583.9 | 2,003.3 | 14.7 | 29.9 | 39.1 | 7.5 | |
| 15.7 | 919.2 | 0.0 | -167.9 | -- | -128.7 | -- | 4.4 | |
| 26.0 | 15,514.1 | 3,900.9 | 821.0 | 23.5 | 14.4 | 19.3 | 2.7 | |
| 10.2 | 1,767.7 | 550.0 | 458.1 | -3.3 | 45.9 | 3.9 | 1.4 | |
| 3.6 | 843.3 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.8 | 1,857.8 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.2 | |
| 13.1 | 909.2 | 369.4 | 12.3 | 7.5 | 5 | 67.8 | 3.4 | |
| 3.3 | 583.4 | 4.0 | -198.4 | -4,917.6 | -166.3 | -- | 7.6 | |
| 18.5 | 2,042.6 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 3.1 |
Shareholding Pattern
View DetailsAbout Sierra Oncology (SRRA)
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective... and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc. Read more
-
Pres, CEO & Director
Dr. Stephen George Dilly M.B.B.S
-
Pres, CEO & Director
Dr. Stephen George Dilly M.B.B.S
-
Headquarters
San Mateo, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sierra Oncology (SRRA)
What is the current share price of Sierra Oncology Inc (SRRA) Today?
The share price of Sierra Oncology Inc (SRRA) is $54.99 (NASDAQ) as of 01-Jul-2022 09:30 EDT. Sierra Oncology Inc (SRRA) has given a return of 34.9% in the last 3 years.
What is the current PB & PE ratio of Sierra Oncology Inc (SRRA)?
Since, TTM earnings of Sierra Oncology Inc (SRRA) is negative, P/E ratio is not available.
The P/B ratio of Sierra Oncology Inc (SRRA) is 5.13 times as on 01-Jul-2022, a 17 premium to its peers’ median range of 4.39 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-2.99
|
2.94
|
|
2020
|
-2.18
|
1.80
|
|
2019
|
-0.01
|
0.01
|
|
2018
|
-0.05
|
0.03
|
|
2017
|
-0.09
|
0.04
|
What is the 52 Week High and Low of Sierra Oncology Inc (SRRA)?
The 52-week high and low of Sierra Oncology Inc (SRRA) are Rs -- and Rs -- as of 25-Jun-2026.
What is the market cap of Sierra Oncology Inc (SRRA)?
Sierra Oncology Inc (SRRA) has a market capitalisation of $ 1,343 Mln as on 01-Jul-2022. As per SEBI classification, it is a company.
Should I invest in Sierra Oncology Inc (SRRA)?
Before investing in Sierra Oncology Inc (SRRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.